Key Takeaways
- • Healthcare private equity deal value surged to a record $191 billion in 2025, exceeding the previous high set in 2021, with 445 buyouts announced marking the second-highest annual volume on record.
- • Despite strong 2025 performance, North American healthcare PE deal volume remained essentially flat year-over-year between 2024 and 2025, while deal counts for health care services nationwide declined 18.5% over the preceding year.
- • Exit activity rebounded sharply in 2025, with exit value jumping from $54 billion in 2024 to $156 billion in 2025, driven by a significant increase in mega-deals; exits exceeding $1 billion rose from 16 deals in 2024 to more than 40 in 2025.
- • Large deals exceeding $1 billion drove record deal value across all transaction sizes, signaling continued concentration of capital in marquee opportunities despite headwinds in mid-market segments.
- • Elevated dry powder levels and a growing cohort of sponsor-owned assets reaching the end of their fund lifecycles are expected to sustain deal activity through 2026, though easing interest rates and shrinking dry powder levels present structural shifts in the market environment.
Summary
Healthcare private equity underwent a significant reshaping in 2025 after a period of restraint, delivering record financial performance that masks underlying volatility across deal segments. According to Bain's 2026 Global Healthcare Private Equity Report, disclosed deal value exceeded an estimated $191 billion in 2025, surpassing the previous peak of $190 billion recorded in 2021. This surge reflected robust institutional appetite for healthcare assets, with 445 buyouts announced—the second-highest annual total behind 2021's activity levels. The market's resurgence followed a second-quarter tariff-related pause that temporarily disrupted momentum.
The rebound was heavily concentrated in large transactions. Deal counts grew across all size categories, but mega-deals exceeding $1 billion provided the primary engine for record value creation. This concentration persists despite recent headwinds: North American deal volume remained essentially flat between 2024 and 2025, while private equity deals for healthcare services nationwide declined 18.5% year-over-year from the second quarter, indicating underlying softness in mid-market segments and regional variability in activity.
Exit momentum accelerated sharply, representing a critical shift for portfolio companies held since prior fund vintages. Exit value jumped from $54 billion in 2024 to an expected $156 billion in 2025—nearly a threefold increase. The volume of exits exceeding $1 billion grew from 16 deals in 2024 to more than 40 in 2025, driven substantially by sponsor-to-sponsor transactions that rebounded from post-pandemic lows. Public market opportunities remained actively pursued by private equity firms seeking liquidity events for mature portfolio assets.
Provider services, biopharma, and healthcare IT remain the largest market segments driving capital deployment. Medtech has demonstrated outsized growth momentum since 2020, reflecting structural secular demand and recurring revenue characteristics that appeal to institutional investors. The market dynamics reflect two complementary tailwinds: substantial dry powder accumulated across fund vintages awaiting deployment and a maturing cohort of sponsor-owned assets reaching the end of their typical hold periods. These factors are anticipated to sustain elevated dealmaking through 2026, though evolving regulatory frameworks, operational challenges, and shifting market dynamics are introducing cautious considerations for investors evaluating entry valuations and value creation levers in an increasingly competitive landscape.
The rebound was heavily concentrated in large transactions. Deal counts grew across all size categories, but mega-deals exceeding $1 billion provided the primary engine for record value creation. This concentration persists despite recent headwinds: North American deal volume remained essentially flat between 2024 and 2025, while private equity deals for healthcare services nationwide declined 18.5% year-over-year from the second quarter, indicating underlying softness in mid-market segments and regional variability in activity.
Exit momentum accelerated sharply, representing a critical shift for portfolio companies held since prior fund vintages. Exit value jumped from $54 billion in 2024 to an expected $156 billion in 2025—nearly a threefold increase. The volume of exits exceeding $1 billion grew from 16 deals in 2024 to more than 40 in 2025, driven substantially by sponsor-to-sponsor transactions that rebounded from post-pandemic lows. Public market opportunities remained actively pursued by private equity firms seeking liquidity events for mature portfolio assets.
Provider services, biopharma, and healthcare IT remain the largest market segments driving capital deployment. Medtech has demonstrated outsized growth momentum since 2020, reflecting structural secular demand and recurring revenue characteristics that appeal to institutional investors. The market dynamics reflect two complementary tailwinds: substantial dry powder accumulated across fund vintages awaiting deployment and a maturing cohort of sponsor-owned assets reaching the end of their typical hold periods. These factors are anticipated to sustain elevated dealmaking through 2026, though evolving regulatory frameworks, operational challenges, and shifting market dynamics are introducing cautious considerations for investors evaluating entry valuations and value creation levers in an increasingly competitive landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.